Teva's thrice-weekly Copaxone approved in Russia
Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) today revealed that the Russian Ministry of Health has approved the Marketing Authorization license for three-times-a-week Copaxone (glatiramer acetate injection) 40mg/mL, a new dose of the drug for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
This formulation of Teva’s blockbuster MS drug Copaxone will allow for a less frequent dosing regimen for patients with RRMS in Russia.
“For more than 20 years, Teva has been committed to safe and tolerable treatments options for patients with multiple sclerosis. The availability of three-times-a-week Copaxone 40mg/mL is a significant advancement for the multiple sclerosis patient community in Russia,” said Rob Koremans, president and chief executive of Global Specialty Medicines at Teva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze